Case–control study of calcification of the hepatic artery in chronic hemodialysis patients: Comparison with the abdominal aorta and splenic artery

Okuda, Kunio; Kobayashi, Susumu; Hayashi, Haruyuki; Ohtake, Yoshio; Nakajima, Kiyokazu; Yoshida, Hiromichi; Kashima, Tomoko; Irie, Yasubumi

doi:10.1046/j.1440-1746.2002.02653.x

Cited by 21 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At baseline, TAC prevalence rate was 27%, this prevalence is similar to that of aortic calcifications reported in healthy control groups for hemodialysis patients, ranging from (17.3% in females and 22.1% in males) in one study from Japan 9 and reaching 37.5% in a more recent European study 10 . A considerably higher prevalence of 63% was shown in H einz N ixdorf R ecall study where the participants had a worse cardiovascular risk profile, and TAC was defined to include both ascending, transverse and descending aorta rather than the ascending and descending aorta only in MESA 11 .…”

Section: Discussionsupporting

confidence: 78%

Risk Factors for the Development and Progression of Thoracic Aorta Calcification

et al. 2015

View full text Add to dashboard Cite

Background Vascular calcification independently predicts cardiovascular disease (CVD) and computed tomography (CT) is a useful tool to evaluate and quantify not only coronary but also thoracic aortic calcification (TAC). Previous TAC progression reports were limited to dialysis and renal transplant patients. This is the first study to evaluate TAC progression in a large multi-ethnic cohort without clinically evident CVD at entry. Methods Non-contrast enhanced cardiac CT were obtained in 5886 of 6814 MESA participants (mean age 62 years; 48% males; 40% white, 27% Black, 21% Hispanic, 12% Chinese. Baseline and follow-up TAC scores were derived. Results 4308(73%) participants had no detectable baseline TAC. Mean follow-up duration was 2.4±0.8 years, during which 12% developed TAC. The overall incidence rate was 4.8%/year and was greater with age across gender and ethnic groups; TAC incidence was significantly lower in blacks than whites. After adjustment for follow-up duration, regression analyses showed age, systolic blood pressure, antihypertensives, and smoking were associated with incident TAC. 1578(27%) participants had TAC at baseline with a positive association between average annual TAC change and baseline age. While the overall median change was 32.9 (−1.4, 112.2) Agatston units, 27% showed an annual score change of ≥100 and blacks showed the lowest median across ethnic groups; 22.7 (−3, 86.8). Age, systolic BP, lipid-lowering medication, diabetes and smoking were associated with TAC progression. Conclusion In MESA, traditional CV risk factors were related to both TAC incidence and progression. Blacks had the lowest incidence and median change across ethnic groups, consistent with previous findings for coronary calcification.

show abstract

Section: Discussionsupporting

confidence: 78%

Risk Factors for the Development and Progression of Thoracic Aorta Calcification

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Other reports have shown similar results in HD patients [23] in which age was positively associated with vascular calcification in large and mediumcalibre arteries. Time on HD and total time on renal replacement therapy have been positively associated with vascular calcification, particularly in medium-calibre arteries: each new year on renal replacement therapy increased the risk of having vascular calcifications by approximately 15% [24] .…”

Section: Clinical Impact Of Vascular Calcificationsupporting

confidence: 77%

Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis

et al. 2011

View full text Add to dashboard Cite

Vascular calcification plays a major role in cardiovascular disease, which is one of the main causes of mortality in chronic kidney disease patients. Vascular calcification is determined by prevalent traditional and uraemia-related (non-traditional) risk factors. It occurs mainly in the arteries, which are classified into three types according to their size and structural characteristics. In addition, vascular calcification has been associated with bone loss and fractures in chronic kidney disease patients and the general population, stressing the fact that both disorders can share pathogenetic pathways. The strategies to control vascular calcification involve several measures, chief among them the control of hyperphosphataemia. Furthermore, it has been recently described that strategies that reduce bone resorption and increase bone mineralization may decrease the risk of vascular calcifications; however, this approach still remains controversial. The mechanisms involved in vascular calcification are complex and not yet fully understood. Phosphorus plays a major role, while other factors related to bone formation have been recently identified.

show abstract

“…Vascular calcification is not a random process in chronic HD patients. For example, calcification of the internal thoracic or hepatic arteries is unusual [15,16]. Valvular calcifications often start at the site of valve insertion, in particular the mitral annulus, and then extend in the direction of the cusps.…”

Section: Morphologic and Biochemical Featuresmentioning

confidence: 99%

When man turns to stone: Extraosseous calcification in uremic patients

Floege

2004

Kidney International

View full text Add to dashboard Cite

A 53-year-old man lost a kidney 35 years ago after an accident. Hypertension was detected 18 years ago, but he declined treatment. Last year he presented to the Aachen University Hospital with end-stage renal disease (ESRD), presumably due to hypertensive renal damage. Ambulatory peritoneal dialysis (PD) was started. In view of recurrent compliance problems, including skipping of PD exchanges, a transfer to hemodialysis (HD) was planned, which he refused. Finally, he was admitted again with uremic gastritis, pericardial effusion, polyneuropathy, and a urinary tract infection. The PD dose was increased, appropriate therapy for his medical problems was initiated, and his condition improved. Despite these measures, his serum phosphate rose from usual levels of 2.5 to 3.0 mmol/L to a maximum of 4.8 mmol/L. The serum calcium remained normal. He admitted dietaryThe Nephrology Forum is funded in part by grants from Amgen, Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorporated; and Bristol-Myers Squibb Company.

show abstract

Case–control study of calcification of the hepatic artery in chronic hemodialysis patients: Comparison with the abdominal aorta and splenic artery

Abstract: The hepatic artery is far less frequently calcified than are the abdominal aorta and splenic artery. This may be a teleologic phenomenon of the liver.

Cited by 21 publications

References 8 publications

Risk Factors for the Development and Progression of Thoracic Aorta Calcification

Risk Factors for the Development and Progression of Thoracic Aorta Calcification

Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis

When man turns to stone: Extraosseous calcification in uremic patients

Contact Info

Product

Resources

About